The FDA has issued warning letters to telehealth companies regarding their marketing of compounded GLP-1 weight-loss drugs, with reports varying on the exact number of letters sent, ranging from 25 to 30. The warnings appear to be part of a crackdown on what is described as "illegal marketing" of these compounds. The move has reportedly led to a decline in the shares of at least one company involved in the sector.